Pacific Biosciences of California, Inc. PACB
Nov 5, 2026, 10:22 AM EST
- YTD
- +39.25%
- 1 year
- +35.63%
- Market cap
- 805.39M
- Revenue (ttm)
- 173.15M
- Profit margin
- -227.69%
- EPS (ttm)
- -0.43
- Shares out
- 294.32M
- Forward P/E
- -2.84
- YTD return
- +39.25%
- 1-year return
- +35.63%
- Volume
- 6.38M
- Avg volume
- 12.25M
- Open
- 2.24
- Previous close
- 2.55
- Day's range
- 2.23 – 2.69
- 52-week range
- 1.07 – 3.44
- Beta
- 2.01
- Analysts
- Buy
- Price target
- 3.02 (+16.0%)
5D -0.09 (-3.30%)
Key statistics
- Enterprise value
- 989.12M
- PEG ratio
- 0.00
- Price / sales
- 3.28
- Price / book
- 1.17
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -28.20%
- Free cash flow
- -190.76M
- Total cash
- 471.15M
- Total debt
- 920.75M
- Return on equity
- -64.80%
- Short % of float
- 21.05%
- 50-day average
- 2.01
- 200-day average
- 2.02
Analyst view
Consensus: buy
- Target (low)
- 2.00
- Target (mean)
- 3.02
- Target (high)
- 6.00
- Strong buy1
- Buy6
- Hold8
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.17551.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.20 | -0.17 | +0.03 | +15.00% |
| Aug 7, 2024 | Jun 1, 2024 | -0.24 | -0.20 | +0.04 | +16.67% |
| May 9, 2024 | Mar 1, 2024 | -0.26 | -0.26 | 0.00 | 0.00% |
| Feb 15, 2024 | Dec 1, 2023 | -0.31 | -0.27 | +0.04 | +12.90% |
| Oct 30, 2023 | Sep 1, 2023 | -0.30 | -0.27 | +0.03 | +10.00% |
| Aug 2, 2023 | Jun 1, 2023 | -0.34 | -0.26 | +0.08 | +23.53% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2024 | UBS | down | Buy | Neutral |
| Nov 11, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Nov 11, 2024 | Piper Sandler | main | Neutral | Neutral |
| Aug 28, 2024 | Scotiabank | main | Sector Outperform | Sector Outperform |
| Aug 13, 2024 | Stephens & Co. | main | Overweight | Overweight |
| Aug 12, 2024 | Morgan Stanley | main | Equal-Weight | Equal-Weight |
About Pacific Biosciences of California, Inc.
Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing solution to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) technology; long-red sequencing; and various reagent kits designed for specific workflow, such as preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. In addition, it provides revio system + sequel systems which conduct, monitor, and analyze single-molecule biochemical reactions in real time; SBB short-read sequencing; onso instrument conducts, monitors, and analyzes SBB biochemical reactions; and SBB consumable, including flow cells, clustering, and sequencing reagent kits. The company serves academic and governmental research institutions; commercial testing and service laboratories; genome centers; public health labs, hospitals and clinical research institutes, and contract research organizations; pharmaceutical companies; and agricultural companies. It markets its products through a sales force and distribution partners in Asia, Australia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.
- Sector
- Healthcare
- Industry
- Medical Devices
- Country
- United States
- Website
- pacb.com
News
Pacific Biosciences of California, Inc. (PACB) Q3 2026 Earnings Call Transcript
Pacific Biosciences of California (PACB) Reports Q3 Loss, Beats Revenue Estimates
What Pacific Biosciences of California (PACB) Said on Its Q3 Earnings Call
Pacific Biosciences Q3 2026 Earnings Call Transcript Pacific Biosciences Narrows FY2026 Sales Guidance from $155.000M-$165.000M to $155.000M-$160.000M vs $158.871M Est
PacBio Announces Third Quarter 2026 Financial Results
Pacific Biosciences of California (PACB) Rises As Market Takes a Dip: Key Facts
10 Health Care Stocks Whale Activity In Today’s Session
12 Health Care Stocks Moving In Wednesday's Intraday Session
Vertiv, Evercore, Brinker, GE HealthCare And Other Big Stocks Moving Higher On Wednesday
Your note
Sign in to keep a note on PACB — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| EIDEL JEFFREY | Officer | Sale | Aug 18, 2024 | 869,938 |
| ERICSON WILLIAM W | Director | Stock Award(Grant) | Jun 17, 2024 | 41,616 |
| HENRY CHRISTIAN O | Chief Executive Officer | Sale | Sep 15, 2024 | 2,497,760 |
| KIM SUSAN G | Chief Financial Officer | Sale | Sep 29, 2024 | 695,654 |
| LIVINGSTON RANDALL S | Director | Stock Award(Grant) | Jun 17, 2024 | 22,821 |
| MILLIGAN JOHN F | Director | Stock Award(Grant) | Jun 17, 2024 | 132,821 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK Investment Management, LLC | 12.20% | 33,406,401 | 64.47M | Sep 29, 2024 |
| Madrone Advisors, LLC | 8.54% | 23,391,915 | 45.15M | Sep 29, 2024 |
| Blackrock Inc. | 8.49% | 23,252,682 | 44.88M | Sep 29, 2024 |
| Edmond De Rothschild Holding S.A. | 7.42% | 20,307,880 | 39.19M | Sep 29, 2024 |
| Vanguard Group Inc | 6.44% | 17,642,804 | 34.05M | Sep 29, 2024 |
| Sumitomo Mitsui Trust Holdings, Inc. | 4.33% | 11,865,766 | 22.90M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| ARK ETF Tr-ARK Innovation ETF | 6.91% | 18,937,397 | 36.55M | Oct 30, 2024 |
| ARK ETF Tr-ARK Genomic Revolution ETF | 4.52% | 12,389,944 | 23.91M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 3.26% | 8,930,679 | 17.24M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.57% | 7,047,500 | 13.60M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.45% | 3,984,497 | 7.69M | Sep 29, 2024 |
| Smallcap World Fund | 1.24% | 3,390,000 | 6.54M | Sep 29, 2024 |
